Oncobiologics (NASDAQ:OTLK) Downgraded to "Sell" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Oncobiologics from “Hold” to “Sell,” although the broader analyst consensus remains “Hold” with a $4.65 price target.
• The company reported a quarterly loss of $0.09 per share, slightly worse than expectations, while revenue of approximately $10,000 fell far short of the $970,000 consensus estimate.
• Oncobiologics priced a $55 million stock-and-warrant offering, creating substantial dilution, even as insiders purchased more than 11.1 million shares over the past 90 days.

Oncobiologics (NASDAQ:OTLK - Get Free Report) was downgraded by Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Saturday.

Several other equities research analysts have also issued reports on the stock. HC Wainwright lifted their price target on shares of Oncobiologics to $1.60 and gave the company a "neutral" rating in a research note on Monday, July 27th. Ascendiant Capital Markets increased their price objective on shares of Oncobiologics from $6.00 to $10.00 and gave the stock a "buy" rating in a research note on Thursday, June 11th. BTIG Research restated a "buy" rating and issued a $4.00 price objective on shares of Oncobiologics in a report on Friday. Finally, Weiss Ratings raised Oncobiologics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Oncobiologics presently has a consensus rating of "Hold" and a consensus price target of $4.65.

Oncobiologics Stock Down 14.9%

Shares of OTLK opened at $0.76 on Friday. The stock has a market capitalization of $112.39 million, a P/E ratio of -0.65 and a beta of 0.82. Oncobiologics has a twelve month low of $0.16 and a twelve month high of $3.39. The company has a 50 day moving average of $1.31 and a 200-day moving average of $0.70.

Oncobiologics (NASDAQ:OTLK - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01). The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.97 million. On average, sell-side analysts anticipate that Oncobiologics will post -0.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Oncobiologics news, Director Ghiath M. Sukhtian acquired 2,525,252 shares of the business's stock in a transaction dated Wednesday, August 12th. The stock was bought at an average cost of $0.99 per share, with a total value of $2,499,999.48. Following the completion of the transaction, the director directly owned 24,617,320 shares in the company, valued at approximately $24,371,146.80. This represents a 11.43% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Faisal Ghiath Sukhtian bought 95,398 shares of Oncobiologics stock in a transaction dated Wednesday, July 29th. The shares were acquired at an average price of $1.05 per share, with a total value of $100,167.90. Following the completion of the purchase, the director directly owned 220,972 shares in the company, valued at $232,020.60. This trade represents a 75.97% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders bought 11,189,359 shares of company stock valued at $7,662,666. Insiders own 1.80% of the company's stock.

Hedge Funds Weigh In On Oncobiologics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. increased its holdings in shares of Oncobiologics by 865.2% in the second quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company's stock valued at $39,000 after purchasing an additional 21,941 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Oncobiologics by 42.7% in the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company's stock valued at $103,000 after purchasing an additional 25,351 shares during the period. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Oncobiologics by 74.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company's stock worth $126,000 after buying an additional 44,063 shares during the last quarter. 11.20% of the stock is owned by institutional investors.

Oncobiologics News Summary

Here are the key news stories impacting Oncobiologics this week:

• Positive Sentiment: BTIG Research reaffirmed its “buy” rating and set a $4.00 price target, implying significant potential upside from recent trading levels. Benzinga analyst rating report
• Positive Sentiment: Management highlighted FDA approval of LYTENAVA, an ophthalmic bevacizumab product intended to address the U.S. wet age-related macular degeneration market. The approval could support future commercialization and revenue growth. Outlook Therapeutics third-quarter results and business update
• Positive Sentiment: Director Ghiath M. Sukhtian purchased 2.53 million shares for approximately $2.5 million, increasing his direct ownership by 11.43%. The insider purchase may be viewed as a vote of confidence in the company’s prospects. SEC insider transaction filing
• Neutral Sentiment: The company’s quarterly loss was $0.09 per share, compared with a $0.44 loss a year earlier, indicating year-over-year improvement but still missing the $0.08 consensus estimate. Zacks quarterly earnings report
• Negative Sentiment: Revenue was only approximately $10,000, far below the $970,000 consensus estimate. The revenue shortfall reinforces concerns about the timing of LYTENAVA’s commercial ramp and near-term cash generation. MarketBeat earnings report
• Negative Sentiment: Oncobiologics priced a $55 million public offering of 55.56 million shares at $0.99 each, along with immediately exercisable warrants carrying a $1.10 strike price. The large offering creates substantial dilution and likely contributed to selling pressure. Public offering announcement

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics' research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source